The midstage, international C-SCAPE study, designed to assess the efficacy and safety of the combination drug elbasvir/grazoprevir with or without ribavirin in treatment-naive, noncirrhotic patients with hepatitis C virus genotypes 2, 4, 5 or 6, achieved its primary endpoint of sustained virological response after participants completed the 12-week regimen, according to a paper published in the Journal of Viral Hepatitis. The study was conducted in seven countries across 30 study sites.
Study tests combo regimen in HCV genotypes 2, 4, 5, 6
Sign up for ANA SmartBrief
Nursing news and information
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.